Posted inHematology-Oncology news Oncology
Targeting ITK with Soquelitinib: A Promising Phase 1 Trial in Relapsed/Refractory T Cell Lymphomas
A phase 1 trial of soquelitinib, a selective ITK inhibitor, showed favorable safety and encouraging efficacy with Th1-skewing immunomodulation in relapsed/refractory peripheral T cell lymphomas, highlighting a novel therapeutic approach.